Cargando…

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

Detalles Bibliográficos
Autores principales:	Guo, Robin, Schreyer, Mark, Chang, Jason C., Rothenberg, S. Michael, Henry, Dahlia, Cotzia, Paolo, Kris, Mark G., Rekhtman, Natasha, Young, Robert J., Hyman, David M., Drilon, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724540/ https://www.ncbi.nlm.nih.gov/pubmed/31485557 http://dx.doi.org/10.1200/PO.19.00021

Ejemplares similares

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer
por: Wirth, Lori J., et al.
Publicado: (2019)

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung's disease
por: Bhattarai, Chacchu, et al.
Publicado: (2022)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway
por: Lin, Chen, et al.
Publicado: (2016)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k81bifdbe9sru4vhjnm6nh7skc